Thomas M. Herndon

Hematology
8600 Old Georgetown Rd
Bethesda, MD 20814

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications

Biosimilars approved for hematologists: lessons from comparative efficacy studies and comparative analytical assessments.

Biosimilars approved for hematologists: lessons from comparative efficacy studies and comparative analytical assessments.

Journal: Blood
Published: December 11, 2025

Biosimilars approved for hematology use: lessons from comparative efficacy studies and comparative analytical assessments.

Biosimilars approved for hematology use: lessons from comparative efficacy studies and comparative analytical assessments.

Journal: Blood
Published: December 11, 2025

Food and Drug Administration regulation of biosimilar products: Improving affordability of biologics for patients with asthma and allergic diseases.

Food and Drug Administration regulation of biosimilar products: Improving affordability of biologics for patients with asthma and allergic diseases.

Journal: The Journal of allergy and clinical immunology
Published: November 17, 2025

Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis.

Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis.

Journal: PloS one
Published: June 09, 2023

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.

Journal: Leukemia
Published: August 31, 2016

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 19, 2013

U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.

U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.

Journal: The oncologist
Published: September 25, 2012
Showing 1-7 of 7

Last Updated: 09/26/2026